Small molecule · Antagonist of adenosine A2A receptor (ADORA2A) · developed by Corvus Pharmaceuticals
Ciforadenant is an oral small molecule that binds adenosine A2A receptors on immune cells, including T-lymphocytes, natural killer cells, macrophages and dendritic cells. It blocks tumor-released adenosine from acting on these receptors, which is intended to reverse adenosine-induced immunosuppression in the tumor microenvironment. It is studied in renal cell cancer, metastatic castration-resistant prostate cancer and multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04280328 | Phase 1 | Multiple Myeloma | Completed | CRVS |
| NCT03237988 | Phase 1 | Healthy Subjects | Completed | CRVS |
| NCT02655822 | Phase 1 | Renal Cell Cancer | Completed | CRVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy SubjectsMetastatic Castration Resistant Prostate CancerMultiple MyelomaRenal Cell Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRVS page.
See CRVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRVS catalysts and pipeline →